Program
felzartamab
Also written as “Felzartamab”, “MOR202” and “TJ202 and Dexamethasone”.
Its studies are mostly in Glomerulonephritis, IGA · Multiple Myeloma · Glomerulonephritis, Membranous · Myasthenia Gravis · Graves Disease, led by 3 companies.
Drug pageFelzartamab: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogenits history only | 117 open or running | phase 3since Nov 11, 2024 | Oct 18, 2019 | Dec 1, 2026phase 3 · NCT06685757 |
| TJ Biopharma | 30 open or running | phase 3since May 14, 2019 | Jan 15, 2019 | none ahead |
| Novartisits history only | 10 open or running | phase 2since Jul 29, 2011 | Jul 29, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of TJ Biopharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 15, 2019First study: phase 2 study in Multiple MyelomaFirst studyNCT03860038 · 113 enrolled · China, Taiwan
- May 14, 2019Phase 3 study in Multiple MyelomaNCT03952091 · 289 enrolled · China, Taiwan
- Dec 9, 2019Named felzartamabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, MOR202
- Nov 4, 2021Phase 1 study in Lupus Erythematosus, SystemicNCT05140824 · 1 enrolled · China
TargetBeta
“A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| isatuximabrule | Sanofi | phase 3 | 23 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
All 3 TJ Biopharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05140824Lupus Erythematosus, Systemic · China | 1 | Terminated | Dec 14, 2022 | 1 |
| NCT03952091Multiple Myeloma · China, Taiwan | 3 | Completed | Jun 30, 2024 | 289 |
| NCT03860038Multiple Myeloma · China, Taiwan | 2 | Completed | Jan 28, 2023 | 113 |
How it is read
Names in the registry
- “Felzartamab”, 9 entries
- “MOR202”, 2 entries
- “TJ202 and Dexamethasone”, 1 entry
- “TJ202, Lenalidomide and Dexamethasone”, 1 entry
- “TJ202 injection”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 3 studies
- Multiple Myeloma, 3 studies
- Glomerulonephritis, Membranous, 2 studies
- Myasthenia Gravis, 1 study
- Graves Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.